AstraZeneca Expects Exanta Experience To Benefit Future Anticoagulant R&D

AstraZeneca's experience with its failed anticoagulant Exanta (ximelagatran) will provide the company an advantage going forward in developing new oral anticoagulants, VP and Cardiovascular Therapy Area Head Gunnar Olsson maintained

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet